List view / Grid view
29 May 2012 | By GlaxoSmithKline
GlaxoSmithKline plc. announced the start of a Phase III programme...
29 May 2012 | By H. Lundbeck A/S
The pivotal clinical programme is in planning...
29 May 2012 | By Abbott
Latest investigational research findings on HUMIRA®...
28 May 2012 | By Sanofi
The group pledges continuous commitment to diabetes management in China...
25 May 2012 | By Pfizer
The CHMP of the EMA has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU)...
25 May 2012 | By Novo Nordisk
Novo Nordisk receives a positive opinion on recombinant factor XIII product (rFXIII)...
25 May 2012 | By Merck
Merck welcomes the launch of Africa’s first national rotavirus vaccination program...
25 May 2012 | By GlaxoSmithKline
Positive opinion recommending marketing authorisation for Votrient®...
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
24 May 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African…
24 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S announced that the company has established a sponsored Level I ADR programme in the United States...
24 May 2012 | By AstraZeneca
New €224m funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing...
23 May 2012 | By Pfizer
Olivier will succeed David Simmons...
23 May 2012 | By Boehringer Ingelheim
1 Mission 1 Million announces its plans to support ongoing work in atrial fibrillation...
22 May 2012 | By Boehringer Ingelheim
Comprehensive Phase III UniTinA-asthma™ program ongoing...
